Table 4 Ongoing clinical trials in further lines of treatment for SCLC
From: Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges
Clinical trial ID | Phase | Setting | Regimen | Endpoint |
|---|---|---|---|---|
NCT02963090 | II | 2nd line | Pembrolizumab vs topotecan | PFS |
NCT03059667 | II | 2nd line | Atezolizumab vs standard chemotherapy | RR (non-comparative) |
NCT02331251 (PembroPlus) | Ib/II | ≥ 2nd line (solid tumors) | Pembrolizumab plus irinotecan | RP2D |
NCT03253068 | II | 2nd line | Pembrolizumab plus Amrubicin | ORR |
NCT02551432 | II | ≥ 2nd line | Pembrolizumab plus Paclitaxel | RR |
NCT03262454 | II | 2nd line | Atezolizumab + RT | RR |
NCT03026166 | I/II | ≥ 2nd line | Rova-T plus Nivolumab +/− ipilimumab | DLT |
NCT03083691 (BIOLUMA) | II | 2nd line | Nivolumab plus ipilimumab | ORR |
NCT02701400 | II | 2nd -3rd line | Tremelimumab plus Durvalumab +/− RT | PFS ORR |
NCT02554812 | Ib/II | ≥ 2nd line | Avelumab plus utomilumab | DLT OR |